Sabin Vaccine Institute Awarded Funding to Advance Therapeutic Vaccine Development for Chagas Disease

WASHINGTON, D.C. — September 16, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) received $2 million from the Global Health Innovative Technology Fund (GHIT Fund) to develop a new therapeutic vaccine formulation for Chagas disease. Baylor College of Medicine, Eisai Co., Ltd. (Eisai) and Aeras are partnering on this project with the Sabin PDP, based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in Houston, Texas.

Phase 1 Clinical Trial of Human Hookworm Vaccine Successfully Completed

WASHINGTON, D.C. — September 3, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas.

Last week, researchers, academics, doctors and advocates from all over the world gathered in Mexico City, Mexico at the 13th International Congress of Parasitology (ICOPA). Sabin Vaccine Institute (Sabin) President Dr.

The accomplishments and work of Sabin and its three major programs — Vaccine Advocacy & Education, the Sabin Product Development Partnership (Sabin PDP) and the Global Network for Neglected Tropical Diseases (Global Network) — are highlighted in our 2013 Annual Report.

Pages

Subscribe to RSS - Sabin Vaccine Development